Bismarck, ND, United States
Bismarck, ND, United States

The University of Mary is a four year Catholic university near Bismarck, North Dakota.The university is the largest degree granting institution in Bismarck. It has campuses in Rome and Peru, and also operates academic programs at satellite locations in North Dakota , Minnesota, Montana, Wyoming, Kansas, Missouri, and Arizona. It is endorsed by The Newman Guide to Choosing a Catholic College. Wikipedia.


Time filter

Source Type

For women who miss a breast screening appointment, giving a fixed date and time for a new appointment could improve poor attendance and be a cost-effective way to shift national participation trends, according to an analysis led by QMUL For women who miss a breast screening appointment, giving a fixed date and time for a new appointment could improve poor attendance and be a cost-effective way to shift national participation trends, according to an analysis led by Queen Mary University of London (QMUL). In England, participation in breast cancer screening has been falling in the last ten years, getting close to the national minimum standard of 70 per cent, with screening particularly low in areas of socioeconomic deprivation. The NHS Breast Screening Programme (NHSBSP) invites women aged 50-70 to mammographic screening every three years. The usual practice for those who don't attend their first offered appointment is to issue them with a second invitation letter. Some centres supply 'open' invitations, asking women to telephone to make an appointment, while others send an invitation with a fixed date and time, requiring no effort from the invitee to book an appointment. To test how effective each approach is, a randomised controlled trial took place in six NHSBSP centres in England, involving 26,000 women who had not attended their last appointment. The results, published in Lancet Oncology, showed that attendance within 90 days of the first offered appointment was significantly higher for those receiving a timed appointment (22.3 per cent) than those receiving an open invitation (12.3 per cent), and the increase was higher for women with a lower socioeconomic status. Offering a second timed appointment caused an absolute increase in attendance of 10.4 per cent. The greatest absolute increase in attendance was seen in South East London (13.8 per cent), followed by Sheffield (11.5 per cent), Derby (11 per cent), West London (9.6 per cent), Plymouth (8.2 per cent) and Hull (7.4 per cent). Lead researcher Professor Stephen Duffy from QMUL said: "We often feel that it is too difficult to change people's behaviour, and we should just let people do what they do. But this study seems to indicate that fairly simple changes do substantially change behaviour, and can increase the rate of participation of screening." The researchers even found that offering fixed appointments had a substantial benefit with women who hadn't attended a screening appointment in the last six years, and a small benefit with women who hadn't attended for nine years. Offering timed appointments could also be cost-effective if applied when overbooking appointment slots. Professor Duffy explained: "Clinics currently overbook appointments to take account of the fact that those invited don't all turn up, but these decisions sometimes have to be made on incomplete information. This study helps estimate how likely it is a previous non-attender would show up to their second timed appointment, and could be used to aid decisions on how much to overbook on those time slots." The study was funded by the National Health Service Cancer Screening Programmes and Department of Health Policy Research Programme. Although the six sites were spread across England, a limitation of the study is that they might potentially not be representative of the English population overall. Research paper: 'The Effect Of Second Timed Appointments For Non-Attenders Of Breast Cancer Screening In England: A Randomised Controlled Trial'. Prue C. Allgood, Roberta Maroni, Sue Hudson, Judith Offman, Anne E. Turnbull, Lesley Peacock, Jim Steel, Geraldine Kirby, Christine E. Ingram, Julie Somers, Clare Fuller, Anthony G. Threlfall, Rhian Gabe, Anthony J. Maxwell, Julietta Patnick, Stephen W. Duffy. Lancet Oncology. Once the embargo lifts, the paper will be published here: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30340-6/fulltext Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 23,120 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.


News Article | May 24, 2017
Site: www.nature.com

Never have so many private eyes looked down at Earth. In the past decade, about a dozen companies have formed to launch Earth-observing satellites. Few have sought to compete with sophisticated government-built instruments, but that is changing. Private firms have begun to develop satellite radar systems and other advanced technologies in a bid to court scientists and other users, even as the US government is threatening to pare back its stable of satellites. Later this year, for example, the Finnish firm Iceye plans to launch a prototype radar instrument — the first step, the company says, towards a constellation of 20 such probes. Until recently, commercial firms had shied away from pursuing radar satellites because they require heavy instruments and consume a lot of power. For some scientists, the growing variety of commercial data is enabling previously impossible research projects. But others fear that increasing reliance on private satellite observations could short-change science over time, by making data more costly or creating other barriers to access. “If you go the commercial way, you’re going to shrink the user base and you’re going to shrink the amount of knowledge you gain from it,” says Matthew Hansen, a geo­grapher at the University of Mary­land in College Park who uses some private data. Remote-sensing companies typically sell their data to the government and to businesses such as private weather forecasters and agri­cultural firms. They have tended to focus on collecting data in just a few wavelength bands, to provide sharper and more frequent images than government spacecraft can. But various trends — the falling costs of components, the development of small satellites such as CubeSats and improved engineering and manufacturing processes — have allowed firms to pursue more-complex technologies. Several firms are looking to develop satellites equipped with radar, which can gather data at night and through cloud cover — situations in which instruments relying on visible light falter. Iceye’s planned constellation of probes should be able to image a given location many times a day, whereas existing radar-equipped satellites, such as the European Space Agency’s Sentinel-1, return to a given spot only every few days. Other companies with radar projects in development include XpressSAR of Arlington, Virginia, and Urthecast of Vancouver, Canada. Some firms are beginning to explore hyperspectral imaging, which spans a wide range of wavelengths, allowing the detection of specific chemicals. In 2016, Satellogic of Buenos Aires launched two 35-kilogram satellites equipped with custom-designed cameras and light filters. Last month, the company became the first commercial supplier of hyperspectral data. Satellogic’s goal is to fly about 300 satellites, together capable of imaging any location on Earth. And it has already begun to appeal to scientists. The company announced in January that it would give researchers free access to its 30-metre-resolution hyperspectral data. These span optical and near-infrared wavelengths and can help track water pollution and oil spills, and monitor the health of forests and crops. “We are receiving contacts from scientists all over the world,” says Satellogic chief executive Emiliano Kargieman. But most commercial data must be purchased, and some scientists say the cost can limit their usefulness. Unless companies commit to making data archives available to all who need such information, they will freeze out many cash-strapped junior researchers and people in developing countries, Hansen says. And commercial data simply aren’t good enough for many types of study, despite the technical advances. No commercial satellite matches the consistency and stability of the data collected by the US government’s Landsat probes, which have monitored Earth since 1972. Government-funded missions also remain unparalleled in enabling scientists to push frontiers in basic research that may not have immediate applications, says Lorraine Remer, an atmospheric scientist at the University of Maryland in Baltimore. Remer is deputy project scientist for NASA’s planned PACE satellite, and says that she does not know of any instrument aboard a commercial satellite that could produce hyperspectral data to rival those possible with the NASA mission. PACE’s ocean-colour imager will enable researchers to identify specific types of aerosol particle in the air, and plankton types in the ocean. And governments typically provide the raw data that are used to create images, not just the images themselves, adds Andreas Kääb, a geoscientist at the University of Oslo who uses satellite data to study glacier movement. With commercial providers, “once you ask for raw data, you quickly run into problems”, he says. But commercial data may become more enticing if government support for Earth monitoring recedes. In the United States, President Donald Trump has proposed axing three NASA missions in 2018 — including PACE — and scaling back a fourth. “We’re looking at an unpredictable future for Earth-science funding in the US,” Kargieman says. “If we have a capability among the private sector to step in and provide the data that will allow scientists to continue to do research, I think we should do so.”


News Article | May 26, 2017
Site: www.eurekalert.org

A new test, based on a patient's epigenetics, could be an accurate and inexpensive way to find and treat those at highest risk of anal cancer -- a disease with growing incidence in women, men who have sex with men (MSM) and people with HIV A new test, based on a patient's epigenetics*, could be an accurate and inexpensive way to find and treat those at highest risk of anal cancer - a disease with growing incidence in women, men who have sex with men (MSM) and people with HIV. The early research by Queen Mary University of London (QMUL), which was funded by Cancer Research UK, finds that the test could lead to a reduction in painful procedures and minimise the over-treatment of people at low risk. Anal cancer is mostly caused by human papillomavirus (HPV) - the same virus that causes cervical cancer. In 2014, the UK had around 1,300 new cases of anal cancer and 360 deaths. In addition to rising levels in women and MSM, anal cancer is more common in HIV-positive MSM with around 100 cases per 100,000, compared to 25 in HIV-negative MSM, and only 1.5 in men in general. Diagnosis presents many challenges. Full biopsies are painful, and taking a small sample of cells ('cytology') is problematic because lesions can be hidden and clinicians give varying interpretations of results. High-resolution anoscopy, where the anal canal is examined with a high resolution magnifying instrument, is often used as the primary screening tool for high-risk populations but is uncomfortable for the patient, expensive, complex and generates subjective results. Lead researcher Professor Attila Lorincz from QMUL said: "The widespread over-treatment of anal precancerous lesions is necessary today because we don't know which ones will progress to cancer. But this creates a large burden on anoscopy clinics in the UK and the procedures can be detrimental to people's quality of life. Many people are undergoing these procedures unnecessarily, so what we really need is precision medicine to identify those who do need treatment." The research, published in the journal Oncotarget, involved studying anal biopsy specimens from 148 patients in London, including 116 men (mostly MSM). The specimens were analysed to look for genetic markers that may be associated with the presence of anal cancer. The team specifically looked at the patients' epigenetics and found that all of the anal cancers showed the presence of specific epigenetic methylation markers on the patients' EPB41L3 gene (a tumour suppressor gene) and also on certain regions of their viral HPV genome. The results suggests that epigenetic testing may be an accurate and thorough method to indicate whether a patient's lesions are destined to progress to anal cancer. This could reduce the costs, pain and anxiety from other methods of diagnosis, and minimise over-treatment of low risk people. Professor Lorincz added: "We thought this would require a complicated genomic signature involving hundreds of genes, so we were surprised that we could get such an accurate prediction from just two biomarker genes. That's important because the expected cost of the test will be fairly low. "Now that we can identify those at risk, and conversely, those not at risk, we hope to see a big improvement, by making sure that anoscopies and laser or chemical surgery are only given to those who need it." Once developed, the test would involve taking a small sample of cells from the anal canal via a swab and then sending the sample off to a laboratory for epigenetic analysis. While a test could be developed within five years, the researchers caution that the results first need to be confirmed in a much larger study across the UK, and repeated using swab samples rather than the biopsies which were used in the current study. Dr Rachel Orritt, Cancer Research UK's health information officer, said: "This study builds on what we already know about the link between changes to cell DNA and cervical cancer, and shows that similar changes to the DNA in anal cells could suggest anal cancer. "If other studies confirm and build upon these findings, this promising research could be used to develop a less invasive method to help doctors identify people who are at a higher risk of anal cancer and avoid unnecessary procedures for those who are at a lower risk." The researchers say that these types of biomarker - epigenetic methylation biomarkers - are important in a large number of other diseases, and could lead to a completely new approach to diagnostics and drug therapy. Professor Lorincz explained: "These could be the early stages of a discovery of a universal set of biomarkers for any cancer. And there may be implications on therapies, as there are new techniques where the epigenetic pathway can be targeted by drugs. This is going to be the hot new area going forward in the next 15 years, so people need to be paying attention to this space." * 'Epigenetics' describes the naturally-occurring chemical 'tags' on genes which control whether or not they are switched on. Liver cells and kidney cells are genetically identical apart from their epigenetic marks. Research paper: 'Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions'. Attila T Lorincz, Mayura Nathan, Caroline Reuter, Rhian Warman, Mohamed A Thaha, Michael Sheaff, Natasa Vasiljevic, Amar Ahmad, Jack Cuzick, Peter Sasieni. Oncotarget. Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 23,120 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year. * Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. * Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. * Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated. * Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years. * Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years. * Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. * Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www. . Follow us on Twitter and Facebook.


News Article | February 15, 2017
Site: www.eurekalert.org

Women who participate in obstetric and gynaecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London (QMUL). This is the case regardless of whether or not the treatment is found to be effective in the trial. The review of 21 studies* included 20,160 women, and found that participants had 25 per cent better odds of improved health outcomes**, compared with non-participants. The researchers hope the results may lead to more clinicians offering trials to their patients and more women volunteering for trials in a research area that currently faces many challenges. A clinical trial compares the effects of one treatment with another, and normally involves large numbers of volunteer patients in many centres. The results from trials help doctors understand how to treat a particular disease or condition, and are necessary to test the safety and efficacy of new treatments before they are brought into general use. Research on the effect of participation in trials has previously not consistently shown evidence of benefit. This may be because previous work has analysed data from all medical specialities grouped together which could include wide variations in the way care is given within and outside trials. The review, which focuses on pregnancy and reproductive health, is published in BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) and is believed to be the first of its kind. It found that the beneficial effect of participating in a trial was largest when it was a high quality clinical trial, and when the trial tested an intervention that was unavailable outside of the trial. Lead researcher Professor Khalid Khan from QMUL said: "Clinical trials are often perceived as 'experiments', 'risky' or 'dangerous'. However, our findings challenge these misconceptions, and show not only that they are safe but that there is a significant benefit associated with participation, with overall 25 per cent chance of better health outcomes." "Interestingly, we also found that participants still experienced benefits irrespective of whether the treatment in the trial was found to be effective or not." Worldwide over 69 million babies are born annually (776,000 in the UK), but only a small proportion of pregnant women are entered into research studies. Pregnancy and reproductive health is an area with unique challenges, dealing with controversial topics (IVF, contraception, abortion), a lack of research funding (less than one per cent of UK government spend) and ethical/legal implications (studies involving pregnant women). As such, research results from general medicine often inform practise in pregnancy patients, which does not always lead to optimum medical care. Ngawai Moss was a participant of QMUL's EMPiRE trial - a study looking at how to control seizures in pregnant women with epilepsy. She said: "I'm very happy that I took part in a clinical trial and would do it all over again without hesitation. I would tell women who are considering whether to join a clinical trial, that the investment of their time is really quite minimal for the reward. "In my case, the trial was pretty straightforward and mainly involved monthly visits to fill in a questionnaire and have a blood test. It was reassuring to be able to see a medical professional on a regular basis, especially as I had a complicated pregnancy. It meant I had access to the team's medical insight, advice and support on general pregnancy-related issues." Professor Khalid Khan from QMUL added: "Women in general are often unrepresented in research, so we hope this may lead to a shift in attitudes and encourage more clinicians and women to be involved in trials. We also hope that patients recognise that research can be even safer than routine healthcare, due to the additional safeguards in place." The researchers say that it is important to remember that research can still be associated with risk, and it is the duty of researchers and clinicians to inform patients of the potential risk and benefit of engagement in research. QMUL's IBIS 3 Feasibility Study is currently looking to recruit post-menopausal breast cancer survivors. The clinical trial will test three types of medicines in 18 hospitals around the UK to find out the best way to prevent the late recurrence of breast cancer. More information on joining the trial is available on the website or by contacting ibis3help@qmul.ac.uk or 020 7882 3510. For more information, please contact: * Example trials analysed in the review included a trial on the use of heparin and aspirin for women with in vitro fertilization implantation failure, and a trial comparing the success of hormone releasing implants with copper-intrauterine devices as contraceptive methods. ** The review included maternal and neonatal health outcomes such as stillbirth, pre-eclampsia, pregnancy rates, Neural tube defect, spontaneous fetal death, treatment satisfaction, treatment acceptability, infant death, caesarean section rate, successful surgery, severe bleeding (abortion), and fetal outcomes. Research paper: 'Participation in clinical trials improves outcomes in women's health: A systematic review and meta-analysis'. Simrit K. Nijjar, Maria I. D'Amico, Noshali A. Wimalaweera, Natalie A.M. Cooper, Javier Zamora, Khalid S. Khan. BJOG 2017. DOI: 10.1111/1471-0528.14528. Once published, the article can be found here: http://onlinelibrary. Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 21,187 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.


News Article | February 15, 2017
Site: www.eurekalert.org

Vitamin D supplements protect against acute respiratory infections including colds and flu, according to a study led by Queen Mary University of London (QMUL) Vitamin D supplements protect against acute respiratory infections including colds and flu, according to a study led by Queen Mary University of London (QMUL). The study provides the most robust evidence yet that vitamin D has benefits beyond bone and muscle health, and could have major implications for public health policy, including the fortification of foods with vitamin D to tackle high levels of deficiency in the UK. The results, published in the BMJ, are based on a new analysis of raw data from around 11,000 participants in 25 clinical trials conducted in 14 countries including the UK, USA, Japan, India, Afghanistan, Belgium, Italy, Australia and Canada. Individually, these trials yielded conflicting results, with some reporting that vitamin D protected against respiratory infections, and others showing no effect. Lead researcher Professor Adrian Martineau from QMUL said: "This major collaborative research effort has yielded the first definitive evidence that vitamin D really does protect against respiratory infections. Our analysis of pooled raw data from each of the 10,933 trial participants allowed us to address the thorny question of why vitamin D 'worked' in some trials, but not in others. "The bottom line is that the protective effects of vitamin D supplementation are strongest in those who have the lowest vitamin D levels, and when supplementation is given daily or weekly rather than in more widely spaced doses. "Vitamin D fortification of foods provides a steady, low-level intake of vitamin D that has virtually eliminated profound vitamin D deficiency in several countries. By demonstrating this new benefit of vitamin D, our study strengthens the case for introducing food fortification to improve vitamin D levels in countries such as the UK where profound vitamin D deficiency is common." Vitamin D - the 'sunshine vitamin' - is thought to protect against respiratory infections by boosting levels of antimicrobial peptides - natural antibiotic-like substances - in the lungs. Results of the study fit with the observation that colds and 'flu are commonest in winter and spring, when levels of vitamin D are at their lowest. They may also explain why vitamin D protects against asthma attacks, which are commonly triggered by respiratory viruses. Daily or weekly supplementation halved the risk of acute respiratory infection in people with the lowest baseline vitamin D levels, below 25 nanomoles per litre (nmol/L). However, people with higher baseline vitamin D levels also benefited, although the effect was more modest (10 per cent risk reduction). Overall, the reduction in risk of acute respiratory infection induced by vitamin D was on a par with the protective effect of injectable 'flu vaccine against 'flu-like illnesses. Acute respiratory infections are a major cause of global morbidity and mortality. Upper respiratory infections such as colds and 'flu are the commonest reason for GP consultations and days off work. Acute lower respiratory infections such as pneumonia are less common, but caused an estimated 2.65 million deaths worldwide in 2013. Vitamin D supplementation is safe and inexpensive, so reductions in acute respiratory infections brought about by vitamin D supplementation could be highly cost-effective. The study was conducted by a consortium of 25 investigators from 21 institutions worldwide* and funded by the National Institute for Health Research. Joel Winston, Public Relations Manager (School of Medicine and Dentistry) Queen Mary University of London j.winston@qmul.ac.uk Tel: +44 (0)20 7882 7943 / +44 (0)7970 096 188 * Institutions involved in the research: Edmond and Lily Safra Children's Hospital (Tel Hashomer, Israel), Geisel School of Medicine at Dartmouth (NH, USA), Harvard School of Public Health (Boston, MA, USA), Jikei University School of Medicine (Tokyo, Japan), Karolinska Institutet (Stockholm, Sweden), Massachusetts General Hospital (Boston, MA, USA), McMaster University (Hamilton, Ontario, Canada), Medical University of Lodz (Poland), QIMR Berghofer Medical Research Institute (Queensland, Australia), Queen Mary University of London (UK), The Pennsylvania State University (Hershey, PA, USA), Università degli Studi di Milano (Milan, Italy), Universitair ziekenhuis Leuven (Belgium), University of Auckland (New Zealand), University of Birmingham (UK), University of Colorado School of Medicine (Aurora, CO, USA), University of Delhi (India), University of Otago (Christchurch, New Zealand), University of Tampere (Finland), University of Tasmania (Australia), Winthrop University Hospital (Mineola, NY, USA). Research paper: 'Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data'. Martineau et al. BMJ 2017 Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 23,120 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year. The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. The NIHR is the research arm of the NHS. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government's strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (http://www. ).


The International Nurses Association is pleased to welcome Wendy Bryant, RN, to their prestigious organization with her upcoming publication in the Worldwide Leaders in Healthcare. Wendy Bryant is a Registered Nurse with 11 years of experience in her field and an extensive expertise in all facets of nursing, especially medical/surgical nursing. Wendy is currently serving patients as a Charge Nurse within Navarro Regional Hospital in Corsicana, Texas. Wendy Bryant attended the University of Mary Hardin Baylor in Belton, Texas, graduating with her Bachelor of Science Degree in Nursing in 2005. An advocate for continuing education, Wendy is currently pursuing her Master of Science Degree in Nursing with a Family Nurse Practitioner concentration at Kaplan University. She holds additional certifications in Advanced Cardiac Life Support, Basic Life Support, Pediatric Advanced Life Support, and is also EKG and Telemetry Certified. To keep up to date with the latest advances and developments in nursing, Wendy maintains a professional membership with the American Nurses Association. Throughout her career, Wendy has worked in many areas of the nursing field, including pediatrics, geriatrics, home health care, and in hospital settings. She attributes her success to her mother, who has always been a strong influence in her life. When she is not assisting her patients, Wendy enjoys running marathons. Learn more about Wendy Bryant here: http://inanurse.org/network/index.php?do=/4135237/info/ and be sure to read her upcoming publication in Worldwide Leaders in Healthcare.


News Article | December 20, 2016
Site: www.eurekalert.org

The NHS Health Check program in England may have prevented an estimated 4,600 to 8,400 heart attacks, strokes, or death from these causes in its first five years, according to an independent review of the programme led by Queen Mary University of London The NHS Health Check programme in England may have prevented an estimated 4,600 to 8,400 heart attacks, strokes, or death from these causes in its first five years, according to an independent review of the programme led by Queen Mary University of London (QMUL). The programme, which has in the past been considered 'controversial', led to an increase in diagnoses of 30 per cent for diabetes, 50 per cent for hypertension and 80 per cent for chronic kidney disease, and 40 per cent more statins were prescribed, but researchers say there is still room for improvement for treating those at higher risk. NHS Health Check started in 2009 and is the first programme in the world to tackle prevention of heart attacks and strokes by offering a free check to every adult aged 40-74 years. The scheme offers professional advice on lifestyle changes and treatments, including statins, to reduce the risk of heart attack or stroke. This study, published in the British Journal of General Practice, looked at the first five years of the NHS Health Check programme in three London areas (City & Hackney, Tower Hamlets and Newham) and found that: The introduction of this scheme was controversial, say study authors. Statins received adverse publicity and the programme's effectiveness was contested. This was largely based on a review of 16 trials of health checks, of which 12 were conducted before 1994 when neither statins nor modern antihypertensive drugs were in use. Study lead Dr John Robson from QMUL said: "Those who attended NHS Health Checks were substantially more likely to be found with a diagnosis of a new disease, including hypertension, diabetes and chronic kidney disease. We saw a 30 to 80 per cent increase in the number of disease cases found, compared to those who did not attend, and 40 per cent more people were prescribed statins, so these are very substantial gains in public health terms. "If you compare attendance levels with other programmes, such as the bowel screening programme, the coverage here is much better, so one would hope that would translate into earlier opportunities for greater protection for those people. However, there is still room for improvement for NHS Health Checks, especially in terms of ensuring even better treatments for those at higher risk." The study was funded by the Department of Health, but independently conducted. Joel Winston Public Relations Manager (School of Medicine and Dentistry) Queen Mary University of London j.winston@qmul.ac.uk Tel: +44 (0)20 7882 7943 / +44 (0)7970 096 188 Research paper: 'NHS Health Check comorbidity and management: an observational matched study in primary care'. John Robson, Isabel Dostal, Vichithranie Madurasinghe, Aziz Sheikh, Sally Hull, Kambiz Boomla, Chris Griffiths and Sandra Eldridge. British Journal of General Practice. Paper will appear online here after embargo lifts: http://bjgp. Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 21,187 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.


News Article | December 12, 2016
Site: www.eurekalert.org

Treating a type of white blood cell using hormones could improve the development of the placenta in women with pregnancy complications, according to early research led by Queen Mary University of London (QMUL) involving mice and human blood samples Treating a type of white blood cell using hormones could improve the development of the placenta in women with pregnancy complications, according to early research led by Queen Mary University of London (QMUL) involving mice and human blood samples. Pre-eclampsia is a condition in some pregnant women that results in poor maternal blood vessel development in the placenta, leading to poor foetal growth. According to the World Health Organization, it is one of the leading causes of maternal and foetal morbidity and mortality in both the developed and developing world, occurring in 2-8 per cent of all pregnancies. The study, funded by the Wellcome Trust and British Heart Foundation and published in Proceedings of the National Academy of Sciences, looked specifically at neutrophils - short-lived white blood cells that act as the first line of defence in infections - and discovered a new role for them in maintaining a healthy pregnancy. The researchers studied and compared the blood from healthy and pre-eclamptic pregnant women. In the healthy women's blood, they saw that neutrophils interacted with T-cells - another type of white blood cell essential for the immune system. In contrast with the healthy pregnancies, the neutrophils failed to interact with the T-cells in the blood from pre-eclamptic women. The authors suggest that there are signs that, in healthy pregnancies, neutrophils play a role in helping the T-cells to promote blood vessel growth and give rise to normal placental development, suggesting that this could be a potential therapeutic target for pregnancy complications. In tests outside of the human body, the team treated the neutrophils from pre-eclamptic women with pregnancy hormones progesterone and estriol, and found that they were able to begin normal interactions with their T-cells. Further tests in pregnant mice with pre-eclampsia found that if neutrophils underwent the same hormone treatment, and were re-infused into the mouse, placental development began to return to normal. Study author Dr Suchita Nadkarni from QMUL said: "Although we're a long way off and need to confirm these results in a much larger cohort of patients, this could eventually form part of therapy for pregnancy complications. If we could replicate in humans what we've done in mice, and re-introduce the treated neutrophils back into their blood, we may see normal placental development in pregnant women diagnosed with pre-eclampsia. "In the meantime, however, these results give us a much better insight into how the maternal immune system works during pregnancy, and why in some cases it might not work and lead to complications." The study was co-authored by researchers at University of São Paulo, University of Cambridge and University College London Hospitals. Research paper: 'Neutrophils induce pro-angiogenic T cells with a regulatory phenotype in pregnancy'. Suchita Nadkarni; Joanne Smith; Amanda Sferruzzi-Perri, Agata Ledwozyw, Madhav Kishore, Robert Haas, Claudio Mauro, David Williams, Sandra Farsky, Federica Marelli-Berg and Mauro Perretti. Proceedings of the National Academy of Sciences 2016. doi: 10.1073/pnas.1611944114 Queen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 21,187 students from more than 155 countries. A member of the Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research. In the most recent national assessment of the quality of research, we were placed ninth in the UK (REF 2014). As well as our main site at Mile End - which is home to one of the largest self-contained residential campuses in London - we have campuses at Whitechapel, Charterhouse Square, and West Smithfield dedicated to the study of medicine, and a base for legal studies at Lincoln's Inn Fields. We have a rich history in London with roots in Europe's first public hospital, St Barts; England's first medical school, The London; one of the first colleges to provide higher education to women, Westfield College; and the Victorian philanthropic project, the People's Palace at Mile End. Today, as well as retaining these close connections to our local community, we are known for our international collaborations in both teaching and research. QMUL has an annual turnover of £350m, a research income worth £125m (2014/15), and generates employment and output worth £700m to the UK economy each year.


OBJECTIVES:: To describe the head growth of children according to maternal and child HIV infection status. DESIGN:: Longitudinal analysis of head circumference data from 13647 children followed from birth in the ZVITAMBO trial, undertaken in Harare, Zimbabwe between 1997–2001, prior to availability of antiretroviral therapy (ART) or cotrimoxazole prophylaxis. METHODS:: Head circumference was measured at birth, then at regular intervals through 24 months of age. Mean head circumference-for-age Z-scores (HCZ) and prevalence of microcephaly (HCZ <-2) were compared between HIV-unexposed children, HIV-exposed uninfected children (HEU), and children infected with HIV in utero (IU), intrapartum (IP), and postnatally (PN). RESULTS:: Children infected with HIV in utero had head growth restriction at birth. Head circumference Z-scores remained low throughout follow-up in IP children, whilst they progressively declined in IU children. During the second year of life, HCZ in the PN group declined, reaching a similar mean as IP-infected children by 21 months of age. Microcephaly was more common among IU and IP children than HIV-uninfected children through 24-months. HEU children had significantly lower head circumferences than HIV-unexposed children through 12-months. CONCLUSIONS:: HIV-infected children had lower head circumferences and more microcephaly than HIV-uninfected children. Timing of HIV acquisition influenced HCZ, with those infected before birth having particularly poor head growth. HEU children had poorer head growth until 12 months of age. Correlations between head growth and neurodevelopment in the context of maternal/infant HIV infection, and further studies from the current ART era, will help determine the predictive value of routine head circumference measurement. Copyright © 2016 Wolters Kluwer Health, Inc.


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: S-STEM:SCHLR SCI TECH ENG&MATH | Award Amount: 501.25K | Year: 2015

Over the past decade, the Bakken oil boom has had a significant impact on the western North Dakota economy and landscape, resulting in an increased need for wildlife conservationists and environmental scientists to study the energy industrys interactions with the environment. To address this need, The University of Marys Expanding Career Opportunities in Wildlife and Environmental Biology (ECOWEB) project will recruit and enroll 12 academically talented students with financial need in the UM biology programs wildlife conservation or environmental science track. The ECOWEB project will award scholarships ranging from $8,000 to $10,000 per year and enhance student support structures and connections to work-based, research, and graduate school opportunities, so as to ensure students obtain a bachelors degree and successfully transition to STEM employment or graduate school. The ECOWEB Project will have broad and significant impacts in the following ways: 1) enhancing collaborations between UM and other institutions by providing graduate school visits and collaborative research opportunities for S-STEM scholars; 2) enhancing the Biology Departments partnerships with regional biology-related industries and agencies by establishing internship opportunities and seminar events; 3) increasing the number and quality of research opportunities for biology students as well as opportunities to participate and present at professional conferences; 4) increasing the number of biology graduates from populations traditionally underrepresented in STEM; and 5) strategically disseminating evaluation findings within the UM community and to other postsecondary institutions and STEM professionals to advance knowledge and practice about student recruitment and support structures that increase retention to graduation and career preparation.

The ECOWEB project will accomplish three objectives that address local needs. Objective 1: Identify and recruit a diverse population of 12 academically talented students with financial need for the UM biology programs wildlife conservation or environmental science track. The recruitment plan includes digital and print marketing, local and regional high school recruitment, and Open House events that encourage students from groups traditionally underrepresented in STEM. Objective 2: Enhance student support structures to ensure wildlife conservation and environmental science students obtain a bachelors degree within four years. The project will employ strategies and support structures that increase student retention to graduation, enable students to complete their degree in four years, and prepare graduates for successful transition into the wildlife conservation and environmental science workforce or graduate programs. UM Biology Department faculty and student support administrators will collaboratively develop, implement, and assess an array of new and enhanced support services, including: a) an S-STEM cohort model that emphasizes an S-STEM identity and community learning, b) an S-STEM-specific First Year Experience course, c) faculty and peer mentorships, d) a monthly seminar series with industry experts and researchers working in wildlife conservation and environmental science fields, e) biology-related service-learning projects, f) summer research and internship opportunities, and g) student participation in national and regional professional conferences. Objective 3: Enable S-STEM scholars to secure employment in target fields or enter a biology graduate program within one year of graduation. The ECOWEB project will prepare scholars for the STEM workforce or graduate school by providing key support services and activities, including career counseling, GRE preparation, a seminar series, internship opportunities, and field trips to graduate programs. Assessment of the efficacy of these different activities will help contribute to expanding the knowledge base regarding the circumstances under which scholarship projects of this type are successful.

Loading University of Mary collaborators
Loading University of Mary collaborators